Effect of angiotensin II type 1 receptor blockade on kidney ischemia/reperfusion; a gender-related difference [PDF]
, 2016 Fatemeh Moslemi +9 more
openalex +1 more source
British Journal of Clinical Pharmacology, EarlyView.SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić +7 more
wiley +1 more source
Український Журнал Нефрології та Діалізу, 2014 Damage of renal function and dynamics of dyslipidemia in patients with type 2 diabetes mellitus with insufficient glycemic compensation under condition of correction of hypertension with angiotensin II receptor antagonists Introduction.
N.O. Pertseva
doaj +1 more source
Transactivation of the Insulin-Like Growth Factor-I Receptor by Angiotensin II Mediates Downstream Signaling from the Angiotensin II Type 1 Receptor to Phosphatidylinositol 3-Kinase [PDF]
, 2004 Peter Zahradka +3 more
openalex +1 more source
Angiotensin II Type 1 Receptor Antibodies: Great Expectations? [PDF]
American Journal of Transplantation, 2013 K, Tinckam, P, Campbell
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale +5 more
wiley +1 more source
NAFLD‐related hepatocellular carcinoma: The growing challenge
Hepatology, EarlyView., 2022 Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah +2 more
wiley +1 more source
Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection [PDF]
, 2020 James A. Russell +12 more
openalex +1 more source
Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients
British Journal of Clinical Pharmacology, EarlyView.Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel +12 more
wiley +1 more source
L002: Influence of angiotensin II type 1 receptor A/C1166 polymorphism on hypertension in patients with and without coronary atherosclerosis [PDF]
, 1998 Saku, K. +5 more
openalex +1 more source